Medically assisted weight loss, peptide therapy, hormone optimisation and supplementation are often marketed as four separate solutions. In responsible medical care they are better understood as four possible parts of one strategy—selected individually, introduced deliberately and monitored together.
The short answer: the synergy comes from coordination, not from giving every patient all four treatments. Weight management may improve the metabolic environment. Hormone treatment may address a properly diagnosed deficiency or transition. A peptide-based medicine may serve a specific indication. Supplementation may correct a gap or support a defined need. The medical value lies in choosing what belongs—and leaving out what does not.
What “synergy” should mean in medicine
Synergy does not mean a universal “wellness stack”. It means that one part of the plan can change the need for, response to or safety of another. Significant weight change can alter symptoms, blood pressure, glucose control, medication requirements, nutritional intake and hormone results. Hormone treatment can change energy, body composition, fertility considerations and monitoring needs. Supplements can interact with prescribed medicines. Peptide products differ widely in evidence and regulatory status.
If these decisions are made in separate silos, patients can end up with duplicated treatment, contradictory advice or a collection of products without a clear clinical goal. A coordinated plan keeps the medical history, examination, blood results, body composition, symptoms, medicines, goals and follow-up in one picture.
Pillar 1: medically assisted weight loss
Obesity is a chronic, complex disease—not a failure of willpower. The World Health Organization’s 2025 guideline conditionally supports long-term GLP-1 therapy for appropriate adults with obesity, but explicitly places medicine inside comprehensive care that includes healthy nutrition, physical activity and professional support.
That makes medical weight management a logical anchor for many wellness plans. Improving weight-related health may benefit blood pressure, glucose control, mobility, sleep, liver health and cardiovascular risk. The treatment target should therefore be broader than a number on the scale.
The useful questions are: Is prescription treatment indicated? What risks or contraindications matter? How will lean tissue, nutrition, hydration and side effects be managed? Which outcomes will be monitored? What is the maintenance plan? A prescription without those answers is not a complete weight-loss strategy.
Explore Dr Luhard’s medical weight loss approach
Pillar 2: peptide therapy—with precision about what that means
Peptides are short chains of amino acids that can act as signalling molecules. “Peptide therapy” is therefore an umbrella term, not one uniform treatment. Some established medicines—including GLP-1 receptor agonists—are peptide-based. Other products promoted online for recovery, performance or anti-ageing have different levels of evidence and may be unregistered in South Africa.
SAHPRA has specifically warned about the sale and use of unregistered peptide products, the risks of informal supply and the need for appropriate registration, prescription, dispensing and product traceability. Medical supervision cannot turn a poor-quality or unlawfully supplied product into a safe one.
A credible peptide discussion should identify the exact compound, proposed indication, evidence, regulatory status, product source, expected benefit, known uncertainty and monitoring plan. The phrase “peptide therapy” alone is not enough to justify treatment.
Read about responsible peptide consultations
Pillar 3: hormone optimisation without the hype
The word “optimisation” is easily misused. In medical practice, the goal is not to push every hormone to the upper end of a laboratory range. It is to decide whether symptoms and clinical findings point to a genuine hormone-related problem, investigate appropriately, treat when benefits justify risks and reassess the response.
For men, the Endocrine Society recommends diagnosing hypogonadism only when compatible symptoms or signs occur with unequivocally and consistently low testosterone concentrations. Its July 2026 statement again emphasised appropriate early-morning testing. Testosterone is not a generic anti-ageing treatment, and issues such as fertility, haematocrit, sleep apnoea, cardiovascular context and prostate health can materially change the decision.
For women, perimenopause and menopause care is similarly individual. Symptoms, age, medical and family history, previous surgery, treatment goals, route of therapy and personal risks all matter. Hormone therapy can be valuable for appropriate patients, but the right regimen is a shared medical decision—not a standard package.
Weight change can also alter symptoms and hormone measurements. That is why hormone results should be interpreted in context and, where appropriate, reassessed as metabolic health changes rather than treated as permanently fixed numbers.
Pillar 4: supplementation that has a job to do
Supplementation is most defensible when it corrects a demonstrated deficiency, addresses a predictable nutritional gap, supports a specific clinical need or helps manage a treatment-related risk. It is least useful when a long list of products is prescribed simply because “wellness” sounds incomplete without it.
During weight loss, reduced food intake, food intolerance or gastrointestinal adverse effects can affect protein intake, hydration and micronutrient coverage. Some patients have pre-existing vitamin or mineral deficiencies. Others take medicines that influence nutrient status or interact with supplements. Those factors justify assessment—not automatic high-dose supplementation.
The US National Institutes of Health Office of Dietary Supplements maintains evidence-based fact sheets covering effectiveness, safety, recommended amounts and medicine interactions. Its central message is practical: supplements can have unwanted effects, “natural” does not automatically mean safe, and supplements should not replace prescribed treatment or a varied diet.
How the four pillars connect in practice
A coordinated plan looks for cause and consequence. If appetite treatment substantially reduces intake, nutrition and lean-tissue protection become more important. If fatigue continues despite weight improvement, the differential diagnosis should widen rather than automatically adding a hormone or peptide. If hormone therapy is started, changes in symptoms and safety markers should be tracked. If a supplement is added, it should have a defined dose, duration and review point.
Just as importantly, treatments do not always need to start together. Introducing multiple medicines and supplements simultaneously makes it difficult to know what helped, what caused an adverse effect and what can safely be stopped. Sequencing is often a safety tool.
A sensible sequence:
- Define the patient’s main health problem and priorities.
- Review history, current medication, risks, examination findings and relevant investigations.
- Choose the intervention most likely to change the primary problem.
- Add only what has a separate indication or supports the main treatment.
- Monitor benefit, tolerance, safety and adherence using agreed measures.
- Continue, adjust, pause or remove treatment according to the evidence from that patient.
What should be measured?
Measurements should follow the clinical question. Depending on the patient, a doctor may assess weight trajectory, waist circumference, body composition, blood pressure, glucose markers, lipids, liver and kidney function, full blood count, thyroid function, nutritional markers or specific hormone investigations. Symptoms, function, sleep, strength, appetite, adverse effects and quality of life may be just as important as laboratory values.
More tests are not automatically better. A test earns its place when the result can change the diagnosis, choice of treatment, dose, safety plan or follow-up.
Who may benefit from this integrated approach?
It may be useful for adults whose concerns overlap—for example weight gain with fatigue, loss of strength, menopausal symptoms, reduced metabolic health, nutritional risk or previous fragmented treatment. It can also help patients already using several products who want a doctor to simplify the plan and identify what is evidence-based, necessary and safe.
Not every patient will need medication. Not every patient with obesity will need hormone therapy. Not every symptom requires a peptide. Not every abnormal result needs a supplement. The outcome of a good consultation may be a focused prescription, further investigation, a referral, a lifestyle plan or the decision to stop something unnecessary.
Frequently asked questions
Does every wellness patient need all four pillars?
No. The assessment determines which interventions are indicated. Some patients need one pillar, some need a sequence of two or more, and some need investigation or lifestyle support rather than a prescription.
Are GLP-1 medicines a form of peptide therapy?
GLP-1 receptor agonists are peptide-based medicines, but peptide therapy is a much broader term. Different peptide products have different evidence, indications and regulatory status; they should not be treated as interchangeable.
What does responsible hormone optimisation mean?
It means assessing symptoms, context and appropriate investigations, diagnosing a defined problem where present, discussing benefits and risks, and monitoring treatment. It does not mean pushing hormone values as high as possible.
Which supplements should be used during medical weight loss?
There is no universal stack. Supplementation should address a demonstrated deficiency, predictable gap, specific clinical need or treatment-related risk, while accounting for diet, medicine interactions and safe dosing.
Which blood tests are needed?
Testing is individualised. It may include metabolic, haematological, liver, kidney, thyroid, nutritional or hormone investigations when the result would change care.
Where can I consult Dr Luhard?
Dr Luhard consults at Medify, 265 Main Street, Waterkloof, Pretoria. Send a WhatsApp message to 065 559 5412 to request the most appropriate consultation type.
Build one plan—not four disconnected treatments.
Request a doctor-led consultation with Dr Luhard in Waterkloof, Pretoria.
Sources and further reading
- World Health Organization: global guideline on GLP-1 medicines for obesity
- World Health Organization: obesity and GLP-1 therapies—questions and answers
- SAHPRA: peptide products—public information and safety guidance
- Endocrine Society: testosterone therapy for hypogonadism guideline
- Endocrine Society: 2026 statement on testosterone replacement therapy
- The Menopause Society: hormone therapy—benefits, risks and individual factors
- NIH Office of Dietary Supplements: evidence-based supplement fact sheets
This article provides general medical information and does not replace an individual consultation, diagnosis or prescription. Treatment suitability, product legality and regulatory status must be assessed for the individual patient and jurisdiction.